Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Luther

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
JAMA Network Open|May 20, 2022
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use DisorderAugustin G L Vannier, Jessica E S Shay, Vladislav Fomin, et al.
Clinical and Translational Gastroenterology|March 18, 2016
A Novel Resolvin-Based Strategy for Limiting Acetaminophen HepatotoxicitySuraj J Patel, Jay Luther, Stefan Bohr, et al.
European Journal of Gastroenterology & Hepatology|March 5, 2026
Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patientsSoo Young Hwang, Pinghsin Hsieh, Luis Antonio Díaz, et al.
Inflammatory Bowel Diseases|July 18, 2019
Opportunistic Infections Are More Prevalent in Crohn's Disease and Ulcerative Colitis: A Large Population-Based StudyMohammed Zaahid Sheriff, Emad Mansoor, Jay Luther, et al.
American Journal of Medical Genetics. Part A|July 23, 2022
An additional patient with SMAD4-Juvenile Polyposis-Hereditary hemorrhagic telangiectasia and connective tissue abnormalities: SMAD4 loss-of-function and gain-of-function pathogenic variants result in contrasting phenotypesGregory M Gheewalla, Jay Luther, Saumya Das, et al.
Journal of Crohn'S & Colitis|September 11, 2019
Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort StudyNienke Z Borren, William Tan, Francis P Colizzo, et al.
Digestive Diseases and Sciences|July 4, 2020
Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort StudyNienke Z Borren, William Tan, Alison T Jess, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 27, 2018
Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysisNiharika Nalagatla, Katherine Falloon, Gloria Tran, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasiaZain M Virk, Ellen Zhang, Josanna Rodriguez-Lopez, et al.
Alcohol (Fayetteville, N.Y.)|June 12, 2021
Serum HMGB1 associates with liver disease and predicts readmission and mortality in patients with alcohol use disorderAugustin G L Vannier, Ben Wardwell, Vladislav Fomin, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
JAMA Network Open|May 20, 2022
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use DisorderAugustin G L Vannier, Jessica E S Shay, Vladislav Fomin, et al.
Clinical and Translational Gastroenterology|March 18, 2016
A Novel Resolvin-Based Strategy for Limiting Acetaminophen HepatotoxicitySuraj J Patel, Jay Luther, Stefan Bohr, et al.
European Journal of Gastroenterology & Hepatology|March 5, 2026
Glucagon-like peptide-1 receptor agonist reduces risk of alcohol-associated cirrhosis in type 2 diabetes and alcohol use disorder patientsSoo Young Hwang, Pinghsin Hsieh, Luis Antonio Díaz, et al.
Inflammatory Bowel Diseases|July 18, 2019
Opportunistic Infections Are More Prevalent in Crohn's Disease and Ulcerative Colitis: A Large Population-Based StudyMohammed Zaahid Sheriff, Emad Mansoor, Jay Luther, et al.
American Journal of Medical Genetics. Part A|July 23, 2022
An additional patient with SMAD4-Juvenile Polyposis-Hereditary hemorrhagic telangiectasia and connective tissue abnormalities: SMAD4 loss-of-function and gain-of-function pathogenic variants result in contrasting phenotypesGregory M Gheewalla, Jay Luther, Saumya Das, et al.
Journal of Crohn'S & Colitis|September 11, 2019
Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort StudyNienke Z Borren, William Tan, Francis P Colizzo, et al.
Digestive Diseases and Sciences|July 4, 2020
Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort StudyNienke Z Borren, William Tan, Alison T Jess, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 27, 2018
Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysisNiharika Nalagatla, Katherine Falloon, Gloria Tran, et al.
Journal of Thrombosis and Haemostasis : JTH|January 25, 2023
Safety, tolerability, and effectiveness of anticoagulation and antiplatelet therapy in hereditary hemorrhagic telangiectasiaZain M Virk, Ellen Zhang, Josanna Rodriguez-Lopez, et al.
Alcohol (Fayetteville, N.Y.)|June 12, 2021
Serum HMGB1 associates with liver disease and predicts readmission and mortality in patients with alcohol use disorderAugustin G L Vannier, Ben Wardwell, Vladislav Fomin, et al.
Pageof 6